Last updated: 11/07/2018 18:09:21
A Phase III Randomised Multicentre Open-Label Study to Evaluate the Efficacy of AGENERASE (AGN; 600mg BID) in Combination with Low Dose Ritonavir (RTV; 100mg BID) Versus Other Protease Inhibitors (PIs) in HIV-Infected PI-Experienced Adults Over a 16 Week Period: Final Analyses of PRO30017…
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Phase III Randomised Multicentre Open-Label Study to Evaluate the Efficacy of AGENERASE (AGN; 600mg BID) in Combination with Low Dose Ritonavir (RTV; 100mg BID) Versus Other Protease Inhibitors (PIs) in HIV-Infected PI-Experienced Adults Over a 16 Week Period: Final Analyses of PRO30017…
Trial description: A Phase III Randomised Multicentre Open-Label Study to Evaluate the Efficacy of AGENERASE (AGN; 600mg BID) in Combination with Low Dose Ritonavir (RTV; 100mg BID) Versus Other Protease Inhibitors (PIs) in HIV-Infected PI-Experienced Adults Over a 16 Week Period: Final Analyses of PRO30017…
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Pulido F, Katlama C, Marquez M et al. A randomised study investigating the efficacy and safety of amprenavir in combination with low dose ritonavir in protease inhibitor-experienced HIV-infected adults. HIV Med 2004;5(4):296-302
Cattelan AM et al. Switch to amprenavir/ritonavir demonstrated superior efficacy compared to the continuation of a protease inhibitor in multiple PI-experienced HIV-1 infected subjects with virological failure.2nd Int HIV Workshop on Management of Treatment-experienced Patients. San Diego, USA Sept 26-27, 2002.
Medical condition
Infection, Human Immunodeficiency Virus
Product
amprenavir
Collaborators
Not applicable
Study date(s)
December 2000 to Invalid Date
Type
Not applicable
Phase
3
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
Not applicable
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website